European Society of Cardiology Congress 2015
ESC Congress 2015 buzz: Novel LDL lowering treatments
Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the PCSK9 inhibitors versus CETP inhibitors
read more »
Hot Topic siRNA and PCSK9
Dr Peter Lansberg, Academic Medical Center, Amsterdam, the Netherlands discusses this novel approach to PCSK9 targeting.
read more »
IMPROVE-IT: no increased diabetes risk with ezetimibe-statin
A subgroup analysis from IMPROVE-IT showed that there was no excess risk of new-onset diabetes in patients treated with the combination of simvastatin plus ezetimibe. Data were presented by Dr Michael Blazing, Duke University, Durham, USA. The findings provide reassurance after a recent report questioned…
read more »
Statin intolerance: International study
An international survey involving 13 countries in Europe, South America, Asia-Pacific and the USA reinforce recent consensus that statin intolerance is an issue in up to 12% of patients. Importantly, about 10% of these patients receive no lipid lowering therapy after discontinuation of statin. While…
read more »
Sustained lowering of Lp(a) with alirocumab in 4915 patients
In this pooled analysis of 10 clinical trials in the ODYSSEY Clinical trial programme, alirocumab (75/150 mg every 2 weeks) resulted in sustained lowering of lipoprotein(a) [Lp(a)] by 23-29%. In all except two trials (ODYSSEY ALTERNATIVE and ODYSSEY MONO) patients were on background statin therapy….
read more »
ODYSSEY 78 week HeFH data: Clinical perspectives
PCSK9 monoclonal antibody therapy has been shown to be highly efficacious in patients with heterozygous familial hypercholesterolaemia (FH, inherited high cholesterol). However, as patients will require treatment in the long-term, efficacy and safety data are needed. The recent publication of 78 week data from the…
read more »
PCSK9 therapeutics – the next story?
Results from a Phase I trial of a new approach to PCSK9 therapeutics, small interfering RNA (siRNA) were presented at ESC Congress 2015. Professor Steve Nicholls, University of Adelaide, Adelaide, Australia discusses the findings and potential clinical implications of this strategy: what would be the…
read more »
PROFICIO: more evolocumab data
Long-term follow-up of GAUSS patients: durable, well tolerated response to evolocumab In statin-intolerant patients who completed GAUSS-1 and GAUSS-2, evolocumab showed sustained LDL cholesterol lowering over a median 11 month follow-up, with no increase in myalgia, compared with the standard of care. This report pooled…
read more »
ODYSSEY 78-week data in heterozygous FH: PCSK9 FORUM Expert view
ESC Congress 2015, 1 September 2015 Familial hypercholesterolaemia (FH, inherited high cholesterol) represents one of the key priorities for PCSK9 monoclonal antibody therapy. This analysis from the ODYSSEY clinical programme with alirocumab, which has the largest group of heterozygous FH patients studied to date, establishes…
read more »
Managing LDL-C: can we redefine targets?
31st August 2015, London, UK Despite all the consternation and debate about the US versus European guidelines for lipid management, it is important to remember that there are a number of important consistencies. Both guidelines agree that patients at high global risk of cardiovascular disease…
read more »
DYSIS reaffirms unmet clinical needs in ACS patients
Comprehensive results from the DYSIS (Dyslipidemia International Study) II study clearly show that attainment of LDL cholesterol goal in high to very high cardiovascular risk patients is still far from optimal. Overall, nearly 70% of patients with stable coronary heart disease (CHD) did not attain…
read more »
Evolocumab and PROFICIO: consistent LDL response across age, sex and risk groups
ESC Congress 2015, London, 30th August 2015 In an analysis of 3,146 patients from four Phase III trials, evolocumab given either 2-weekly or monthly produced similar LDL cholesterol lowering irrespective of age, gender, glycaemic status or cardiovascular risk. The primary endpoint in this analysis was…
read more »
ESC Translational Hotline: is recombinant HSP-27 a possibility for the future?
ESC Congress 2015, London, 30th August 2015 Heat shock protein 27 (HSP-27) is a novel biomarker that has been previously shown to attenuate atherosclerotic lesion progression and enhance lesion remodelling in an experimental model of atherosclerosis. New data presented at this Translational Science Hotline showed…
read more »
What’s next in the PCSK9 field: small interference RNA therapeutics
ESC Congress 2015, London, 30th August 2015 There were promising data with the reformulated small interference RNA (siRNA) therapeutic targeting PCSK9 (ALN-PCSsc). The study results indicate potential for a quarterly or even twice-yearly subcutaneous injection regimen. Previously a proof of concept Phase I study showed the…
read more »
